Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

Core Insights - Eli Lilly announced positive results from a Phase 2 trial of eloralintide, a selective amylin receptor agonist, showing significant weight reduction in adults with obesity or overweight [1][2][3] - The trial demonstrated mean weight reductions ranging from 9.5% to 20.1% across different dosages of eloralintide compared to a mere 0.4% with placebo [1][3] - The company plans to initiate Phase 3 clinical studies for eloralintide by the end of the year, indicating a commitment to advancing obesity treatment options [1][6] Phase 2 Trial Results - The trial involved 263 participants and lasted 48 weeks, comparing eloralintide dosages (1 mg, 3 mg, 6 mg, 9 mg) against placebo [8] - Primary endpoint results showed: - Eloralintide 1 mg: -9.5% (-10.2 kg; -22.5 lbs) - Eloralintide 3 mg: -12.4% (-13.3 kg; -29.3 lbs) - Eloralintide 6 mg: -17.6% (-18.7 kg; -41.2 lbs) - Eloralintide 9 mg: -20.1% (-21.3 kg; -47.0 lbs) - Placebo: -0.4% (-0.2 kg; -0.4 lbs) [3] Safety and Tolerability - The most common adverse events were mild to moderate gastrointestinal symptoms and fatigue, particularly in higher dose groups [4] - Lower incidence of adverse events was noted with slower dose escalation, with 1 mg and 3 mg arms showing similar rates to placebo [4] Future Plans - Eli Lilly is advancing its pipeline of obesity treatments, emphasizing the importance of molecule specificity [5] - The company is optimistic about eloralintide's potential as a complementary option to existing incretin therapies [5][6] - Plans for Phase 3 enrollment are set to begin by year-end, focusing on eloralintide as a monotherapy for obesity [6]